BCM
FATE icon

Blume Capital Management’s Fate Therapeutics FATE Stock Holding History

Blume Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-600
Closed -$11K – 222
2019
Q1 		$11K Sell
600
-600
-50% -$9.47K 0.01% 180
2018
Q4 		$15K Buy
+1,200
New +$16.7K 0.01% 174

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Blume Capital Management's FATE Position: Q2 2019 in Review

Blume Capital Management sold out of Fate Therapeutics (FATE) in Q2 2019, closing a stake of 600 shares — an estimated $11K sold.

Blume Capital Management first reported a position in FATE in Q4 2018 and held it in 2 quarters. The position peaked at $15K in Q4 2018. 136 funds tracked by Wall St. Rank hold FATE as of Q2 2019.

  • Blume Capital Management reported no remaining Fate Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Blume Capital Management sold 600 Fate Therapeutics shares in Q2 2019, an estimated $11K.
  • Blume Capital Management first reported a position in Fate Therapeutics in Q4 2018 and held it in 2 quarters.
  • Blume Capital Management's Fate Therapeutics position peaked at $15K in Q4 2018.
  • 136 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2019.

Based on Blume Capital Management's 13F filing for Q2 2019, filed 29 Jul 2019.